Technology | 2022.05.04
Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT
PARIS, May 4, 2022 /PRNewswire/ -- Coave Therapeutics (\'Coave\'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announced that research on its AAV-Ligand Conjugates platform (ALIGATER) will...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]isease-at-ascgt-301539078.html
